{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-007620","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.356598+00:00","generated_at":"2026-05-24T18:54:47.514301+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity settles SEC probe over FDA disclosures; pays $2.5M civil penalty","bullets":["Final settlement with SEC: administrative cease-and-desist order, no admission or denial of findings.","Civil penalty of $2.5 million; cash runway into 2026 unchanged per prior guidance.","Resolves investigation into past disclosures about FDA interactions regarding Dovitinib NDA (2021).","All outstanding legal matters now concluded, including securities class action dismissed Feb 2025.","Company reaffirms focus on stenoparib Phase 2 trials in ovarian and small cell lung cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-007620","json":"https://secwatch.observer/filing/0001437749-25-007620.json","markdown":"https://secwatch.observer/filing/0001437749-25-007620.md","text":"https://secwatch.observer/filing/0001437749-25-007620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925007620/0001437749-25-007620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925007620/allr20250313_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:54:47.514301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}